Ticker brief

NRXP

last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
20
authors 14d
4
crowd 14d
+2.6σ

No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.

Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-28 · now +0.90 (−1 bearish … +1 bullish)
Who spoke4
authorgradetrader scoresignalsmean sent
@SuperDuperInvstC-0.9917+0.71
@EmmanuelInvestC-1.111+0.65
@theflynewsC·1+0.00
@cfaryanoconnellC-1.481+0.85
Recent signals20of 20 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-08-28@SuperDuperInvst+0.90Add on dips; expects $5 after breakouts and $7-$11 if FDA approval arrives. — Explicit accumulation strategy with breakout levels and conditional targets.·
2026-08-28@SuperDuperInvst+0.90Start loading NRXP and do not miss the opportunity. — Explicit forward accumulation call, with SLS cited as a prior analogue.·
2026-08-27@SuperDuperInvst-0.10Points to a 7,500-share after-hours bid at $3.59 as liquidity for sellers.·
2026-08-27@SuperDuperInvst+0.60Expects NRXP to rise over time similarly to SLS as SLS approaches its high.·
2026-08-27@SuperDuperInvst+0.80Assigns 90% FDA approval odds and expects a favorable decision to drive NRXP to $7–$11.·
2026-08-26@SuperDuperInvst+0.65Notes steady rises and predicts NRXP will be the next mover.·
2026-08-26@SuperDuperInvst+0.65Urges review of NRXP's large future potential at 3.40.·
2026-08-26@cfaryanoconnell+0.85Add NRXP near $3.45 and sell before year-end between $5.75 and $9.25. — Explicit add with entry area, target range and year-end horizon.·
2026-08-26@SuperDuperInvst+0.85Adding NRXP near 3.45 to sell before year-end between 5.75 and 9.25. — Explicit add with a time horizon and target range.·
2026-08-25@SuperDuperInvst+0.20Reports that three recent picks are rising and up today.·
2026-08-25@SuperDuperInvst+0.40H.C. Wainwright raised its NRXP target to $45 from $40 while maintaining Buy.·
2026-08-25@SuperDuperInvst+0.85Buy and hold NRXP below $3.45. — Urges investors to buy and hold NRXP, using a prior SLS opportunity as comparison.·
2026-08-25@SuperDuperInvst+0.95Load up on NRXP below $3.45 and hold for short, near and long term. — Explicit high-conviction buy-and-hold call tied to expected FDA approval.·
2026-08-21@SuperDuperInvst+0.85Load NRXP while it remains cheap around $3.50. — Urges investors to own and load NRXP before a future upside move.·
2026-08-21@SuperDuperInvst+0.90Buy and hold NRXP, adding on dips. — Explicitly urges NRXP longs to buy, hold and add on dips, comparing it with SLS.·
2026-08-21@SuperDuperInvst+0.90Buy NRXP before larger investors discover it. — Urges entry in NRXP based on market size and anticipated FDA approval readiness.·
2026-08-21@SuperDuperInvst+0.85Accumulate NRXP slowly below $3.50 for short-, near- and long-term horizons. — Explicitly states ongoing accumulation below $3.50 across multiple horizons.·
2026-08-21@SuperDuperInvst+0.95Buy NRXP below $3.50 for a potential move to $7-$13 on FDA approval. — Explicit buy call includes entry, approval probability, timing and upside targets.·
2026-08-20@theflynews+0.00Reports earnings from multiple psychedelic-sector companies without results detail·
2026-08-17@EmmanuelInvest+0.65Reports favorable FDA review progress, manufacturing, funding and multiple CNS program catalysts.·

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.